Is palopegteriparatide FDA-approved, and what does the research show?

What is palopegteriparatide?

Palopegteriparatide is a long-acting form of parathyroid hormone, sold in the United States as Yorvipath ². Parathyroid hormone, or PTH, and calcitriol, the active vitamin D it switches on, are the body's main regulators of calcium and phosphate ¹. They act on bone, the kidneys and the intestine ¹.

The label calls the drug "a prodrug of teriparatide (PTH(1-34))" ². A prodrug is an inactive form that becomes the active drug inside the body. Teriparatide is the first 34 amino acids, the building blocks of proteins, of the 84 in human parathyroid hormone, a stretch the label calls "the biologically active region" ². In palopegteriparatide it is joined by a temporary linker to a carrier made of polyethylene glycol, or PEG, which the label describes as inert ². In the trial paper the drug goes by its research name, TransCon PTH ¹.

Palopegteriparatide is not a wellness, weight-loss or performance peptide. Its label gives one use, "the treatment of hypoparathyroidism in adults" ². In that disease blood calcium can fall and phosphate can rise ¹. The trial paper lists complications that include nerve and muscle irritability, kidney problems and calcium deposits in blood vessels ¹. The standard treatment, called conventional therapy, is active vitamin D with large amounts of calcium, which the paper says "fails to restore the normal physiological effects of PTH" ¹.

Is palopegteriparatide FDA-approved?

Yes, as a prescription drug. FDA approved Yorvipath (palopegteriparatide) on August 9, 2024, under NDA 216490, a new drug application ³. Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ³. The record also lists labeling changes approved on August 3 and October 27, 2026 ³. The label cited here is the October 2026 revision, which names Ascendis Pharma Bone Diseases A/S, of Hellerup, Denmark, as manufacturer ².

That label states one indication: Yorvipath "is indicated for the treatment of hypoparathyroidism in adults" ². It then sets two limits on that use ². The drug "was not studied for acute post-surgical hypoparathyroidism" ². "Acute post-surgical" means arising shortly after an operation.

Second, its dose-adjustment scheme "was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment" ². Albumin-corrected serum calcium is a blood calcium reading adjusted for albumin, a blood protein that carries calcium. It is given in milligrams per deciliter of blood, written mg/dL.

For a reader, the approval means a clinician can prescribe it for that one condition. It is not approved for children: the label says safety and effectiveness "have not been established in pediatric patients" ².

See the FDA status of every peptide, updated weekly.

How does palopegteriparatide work?

What follows is how the approved label describes the drug ². Once injected, it slowly lets go of its carrier: in the label's words, it "releases PTH(1-34) to maintain a continuous systemic exposure" ². The half-life of the released hormone, the time for its blood level to fall by half, is about 60 hours ². At steady state, the label reports "continuous exposure to released PTH throughout the 24-hour dosing period" ².

The released hormone then does the work of the body's own. Natural PTH raises blood calcium and lowers blood phosphate ². The label lists three routes: "stimulating bone turnover to mobilize calcium and phosphate from bone, promoting renal calcium reabsorption and phosphate excretion, and facilitating active vitamin D synthesis" ². So bone gives up some of its mineral, and the kidneys hold on to calcium while passing phosphate into the urine ². Fresh active vitamin D, in turn, lets the intestine absorb more calcium and phosphate ².

The hormone acts through a docking site called the parathyroid hormone 1 receptor ². The label says that receptor is "highly expressed on osteoblasts, osteocytes, renal tubular cells, and in several other tissues" ². Osteoblasts and osteocytes are bone cells, and renal tubular cells line the kidney's small tubes. The label adds one caution about the science: "Exposure-response is not established in subjects with hypoparathyroidism" ². In plain terms, the link between the drug's blood level and its effect has not been worked out in patients.

What does the research show?

The label describes a trial it calls Study 1 ². The paper that reports the same trial calls it PaTHway ¹. It was a phase 3 trial, the large late stage that precedes an approval, and it ran at centers in North America and Europe ¹. It was randomized, double-blind and placebo-controlled ¹, ². Chance decided who received the drug and who received a placebo, a dummy injection, and neither participants nor investigators knew which ¹.

Of 84 adults randomized, 82 received at least one dose: 61 took palopegteriparatide and 21 took placebo ¹. Drug or placebo was given once a day alongside conventional therapy, and 79 of the 82 completed the 26 weeks ¹, ². All had chronic hypoparathyroidism, of at least 26 weeks' standing, and were already taking active vitamin D and calcium ¹. Their mean age was 49, 78 percent were women, and 85 percent had the condition after neck surgery ².

The paper's main measure was a composite, met only if a participant passed every part at week 26 ¹. The parts were normal blood calcium, no standing active vitamin D, standing calcium averaging 600 milligrams a day or less, and no dose increase in the final four weeks ¹. By that measure, 48 of the 61 on the drug (79 percent) passed, against 1 of the 21 on placebo (5 percent) ¹. The paper gives the difference as p < 0.0001, meaning it is very unlikely to be chance ¹.

The label reports the same trial against its own endpoint ². That endpoint lists normal blood calcium, independence from conventional therapy, no dose increase since week 22, no missing data, and a study drug dose within a set limit ². The label's endpoint allows no as-needed doses, where the paper allowed them on up to 7 days of the final four weeks ¹, ².

On the label's count, 42 of the 61 on the drug (68.9 percent) met the endpoint, against 1 of the 21 on placebo (4.8 percent) ². The difference was 64.2 percentage points, with a 95 percent confidence interval of 49.5 to 78.8 ². A confidence interval is the range in which the true figure probably lies.

The label breaks the result into parts ². At week 26, 58 of the 61 on the drug needed no active vitamin D, against 5 of the 21 on placebo ². The label's "independence from therapeutic dose of calcium," meaning a standing dose averaging no more than 600 milligrams a day and no as-needed doses, was reached by 53 of the 61, against 1 of the 21 ². Blood calcium was in the normal range in 49 of the 61, against 10 of the 21 ².

After week 26 the trial continued as an open-label extension, in which everyone knows what is given ¹, ². Among the 61 first assigned to the drug, the share meeting the label's endpoint fell to 39.3 percent (24 of 61) at both week 52 and week 78 ². When a higher dose was allowed, 39 of the 61 (64 percent) at week 52 kept normal calcium without active vitamin D or treatment-level calcium ². At week 78 the figure was 40 of the 61 (66 percent) ². The label notes that "Some patients may require an increase in the YORVIPATH dose over time to maintain the same therapeutic effect" ².

The paper reports two further findings from the blinded 26 weeks ¹. Mean calcium in a 24-hour urine collection fell from 392 to 220 milligrams in the drug group, and from 329 to 292 in the placebo group ¹. That matters, the paper says, because long-term conventional therapy may raise the risk of kidney stones and chronic kidney disease ¹. Scores on a hypoparathyroidism symptom questionnaire, and on the physical-functioning part of a general health survey, improved more with the drug than with placebo ¹.

The authors attach a caution to those scores ¹. Participants knew their own calcium and vitamin D doses ¹. The large cut in those doses "has the potential for a degree of functional unblinding and may have contributed to changes in patient-reported outcomes" ¹. The maker, Ascendis Pharma, paid for the trial, and seven of the paper's authors were its employees ¹.

The paper also describes an earlier hormone treatment, recombinant human PTH(1-84), a lab-made copy of the full-length hormone, as an add-on to conventional therapy ¹. That product has its own page in this library, under parathyroid hormone. PaTHway compared palopegteriparatide with placebo, not with that product ¹.

Some things have not been studied. Neither the label nor the paper reports body weight as an outcome ¹, ². The label says long-term animal studies of the drug's potential to cause cancer "have not been conducted" ². The paper says its view of long-term effects was "limited by trial duration" ¹.

What are the side effects?

The label's side-effect table covers the trial's 26 blinded weeks and sets 61 people on the drug beside 21 on placebo ². Injection-site reactions were reported by 24 of the 61 (39 percent), against 1 of the 21 (5 percent) ². Headache affected 13 (21 percent) against 2 (10 percent), and diarrhea 6 (10 percent) against 1 (5 percent) ². Back pain (5), throat pain (4) and hypercalcemia (5), blood calcium that runs too high, were reported only in the drug group ².

A group the table calls "vasodilatory signs and symptoms," meaning effects of widened blood vessels, affected 17 of the 61 on the drug (28 percent) and none on placebo ². The group counts dizziness, vertigo, palpitations, fainting and near-fainting, drops in blood pressure on standing, and postural orthostatic tachycardia syndrome ².

Hypercalcemia was more common with the drug ². At least one reading above the normal range was recorded in 33 of the 61 (54.1 percent), against 2 of the 21 on placebo (9.5 percent) ². A reading above 12 mg/dL was recorded in 8 of the 61 (13.1 percent) and in no one on placebo ². Hypercalcemia with symptoms was reported in 8 percent of those on the drug, and "all occurred within the first 3 months" ². One participant accidentally took about three times the prescribed dose for more than a week, reached 16.1 mg/dL and was hospitalized ².

The trial paper counts every adverse event, whether or not it was tied to the drug ¹. By that count, 50 of the 61 on the drug (82 percent) and all 21 on placebo had at least one ¹. Hypocalcemia, blood calcium that runs too low, was reported in 6 of the 61 on the drug (10 percent) and 9 of the 21 on placebo (43 percent) ¹.

Serious events were reported in 5 of the 61 on the drug (8 percent) and 3 of the 21 on placebo (14 percent) ¹. One of the five, hypercalcemia that needed hospital care, was judged related to the drug ¹. One man in the drug group, over 70 and with several cardiovascular risk factors, died of a cardiac arrest that was judged unrelated to treatment ¹.

The label carries seven warnings ². The first concerns allergy: "Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria have been reported in patients treated with parathyroid hormone (PTH) analogs, including YORVIPATH" ². Anaphylaxis is a severe whole-body allergic reaction, angioedema is deep swelling under the skin, and urticaria is hives. The label marks this warning as changed in August 2026, and it lists the same reactions among reports received since approval ². Its one contraindication is "a history of severe hypersensitivity to palopegteriparatide or any of the inactive ingredients of YORVIPATH" ².

Three warnings concern calcium ². Serious hypercalcemia "requiring hospitalization" has been reported, and the label says the risk "is highest when starting or increasing the dose" ². Serious hypocalcemia has also been observed, and that risk "is highest when YORVIPATH is abruptly discontinued" ². The label warns as well that taking the daily dose as two injections "increases the variability of the total delivered dose" ².

Two more warnings concern the heart and circulation ². Orthostatic hypotension, a fall in blood pressure on standing, "has been reported with YORVIPATH" ². In people who take digoxin, a heart drug, high calcium "may predispose patients to digitalis toxicity" ².

One further warning concerns osteosarcoma ². The label says: "An increased incidence of osteosarcoma (a malignant bone tumor) has been reported in male and female rats treated with PTH analogs, including teriparatide" ². In people, osteosarcoma has been reported in patients treated with teriparatide since it went on sale ². The label adds that "an increased risk of osteosarcoma has not been observed in observational studies in humans" ².

On that ground Yorvipath "is not recommended in patients who are at increased risk of osteosarcoma" ². The label's list includes people with open epiphyses (growth plates that have not closed) and "Metabolic bone diseases other than hypoparathyroidism, including Paget's disease of bone" ². It also names unexplained rises in alkaline phosphatase, a blood enzyme, and bone metastases or past skeletal cancers ². Past radiation therapy involving the skeleton and hereditary disorders that predispose to osteosarcoma complete the list ².

Some groups have little or no data. Pregnancy data are "insufficient to identify a drug-associated risk," and there are "no data available" on the drug in breast milk ². The trial had too few participants aged 65 or older to show whether they respond differently ². Across the clinical studies, 7 of 139 treated patients (5 percent) developed low-level antibodies against PEG ². One of the 139 had low-titer antibodies against PTH, which the label calls "non-neutralizing" ².

In sport

Palopegteriparatide is not named on WADA's 2026 Prohibited List, and neither is teriparatide or parathyroid hormone ⁴. WADA, the World Anti-Doping Agency, lists peptide hormones in section S2 ⁴. Under S2.2 that section names testosterone-stimulating peptides, corticotropins, growth hormone and growth hormone releasing factors ⁴. It names no parathyroid hormone product there or in any other section ⁴.

What JumpstartMD offers

JumpstartMD does not prescribe palopegteriparatide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.